Kanazawa University (KU)
金沢大学

Japan

Established nearly seven decades ago but with roots stretching back over a century and a half, Kanazawa University has a proud tradition of contributing to the development of Japan and the world. Only two and a half hours by bullet train from Tokyo, the university has become the leading university on the Sea of Japan coast, with more than 10,000 students enrolled in various undergraduate and postgraduate courses.

Embracing globalization

Kanazawa University is strongly committed to implementing global standards for education, training and research. Realizing the importance of establishing networks and collaboration in these areas, the university has recently developed new goals to help it to address the challenges of the future. In particular, it will further its contribution to society by promoting international and interdisciplinary education and research through establishing the Kanazawa University Model for Globalization, which will consolidate Kanazawa University’s place at the centre of higher education and research in East Asia.

Strengthening priority research and Nano Life Science Institute (NanoLSI)

Kanazawa University is cultivating the full spectrum of research — from fundamental investigations to technology-related studies. In particular, Kanazawa University’s five priority research areas are nanoscience research using innovative atomic force microscopy techniques; nutrition-related diseases; cancer progression; cultural-resource studies; and innovative material sciences based on supramolecules. As one of the outcomes, Kanazawa University established Nano Life Science Institute (NanoLSI) which was selected as a World Premier International (WPI) research center by the Japanese government in 2017. NanoLSI challenges to understand nanoscale mechanisms of life phenomena by exploring “uncharted nano-realms.”

Promoting interdisciplinarity

Kanazawa University is adopting a collaborative and network-based approach to foster outstanding researchers who work internationally and across disciplines to engage in new challenges that require breaking conventional molds. To this end, the university established the Institute for Frontier Science Initiative (InFiniti) in 2015 to further promote interdisciplinary research and foster global scientists. The 16 research units in the initiative are primarily led by young principal investigators in conjunction with unit leaders.

Encouraging brain circulation

With its goal of being “a research university dedicated to education, while opening its doors to local and global society,” Kanazawa University seeks to be a hub for top-class education and research in East Asia. It aims to provide a world-class international research environment that attracts excellent young researchers who are inspired to tackle new challenges.

1 August 2018 - 31 July 2019

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for Kanazawa University (KU) published between 1 August 2018 - 31 July 2019 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

AC	FC
88	31.13

Outputs by subject (FC)

Subject	AC	FC
Life Sciences	32	8.96
Physical Sciences	20	5.08
Earth & Environmental Sciences	17	1.92
Chemistry	29	16.96

Highlight of the month

Tackling drug resistance in lung cancer

A Kanazawa University–led team has discovered why some patients with lung cancer develop resistance to osimertinib, a potent and selective drug inhibitor of a protein called EGFR.

The researchers showed that osimertinib can stimulate AXL, a surface receptor found on cancer cells, and that activation of this protein makes cells more tolerant to the drug.

In patient samples, lung tumours with high expression of AXL tended to have lower response rates to EGFR-targeted drugs. And in mice, combined treatment of an AXL inhibitor together with osimertinib led to more prolonged tumour regression than treatment with either agent alone.

The team propose trying a similar strategy in patients to prevent the development of drug resistance to osimertinib — and indeed just such a combination trial is currently ongoing in Taiwan.

Supported content